BIO Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories (BIO) has drawn attention after recent share performance data showed a decline of about 2% over the past month, alongside a gain of roughly 27% over the past three months. At a share price of US$377.71, Bio-Rad Laboratories has seen short term share price momentum cool over the past month. However, the 90 day share price return of about 27% and 1 year total shareholder return of roughly 27% suggest sentiment has improved compared with the much weaker 5 year total...

BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.

Bio-Rad Laboratories (NYSE:BIO) is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective approach to acquisitions. Speaking at a Bernstein conference, Chief Financial Offic

Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.

BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.

Bio-Rad Laboratories has delivered a sharp mix of outcomes for long term holders, with the stock down about 52.9% over 5 years even as shorter term returns have turned positive. This puts the spotlight on what its current share price implies about the cash the business can generate. With the valuation lens focused on cash flows through a Discounted Cash Flow (DCF) framework, the question is how well today's market price lines up with the stream of money the company may produce for...

A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.

Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.

BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.

When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma demand. The news hit European supplier Sartorius AG, which traded lower […]

Digital PCR revenue surged over 20% as clinical diagnostics grew.

Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Q2 earnings and new guidance put Bio-Rad Laboratories in focus Bio-Rad Laboratories (BIO) drew investor attention after reporting second quarter 2026 results alongside fresh guidance. Sales held at US$651 million year over year, while net income and earnings per share from continuing operations increased. The company now expects third quarter 2026 revenue to be flat compared with the second quarter, which it describes as a typical pattern. Management guidance also points to a mid single digit...

Biocon’s updated valuation work now points to a fair value price target of ₹429.67, compared with the earlier figure of ₹416.53. Recent research on peers in life sciences and diagnostics highlights how analysts are weighing profitability plans and execution risk when assigning price targets, which helps explain why the shift for Biocon is measured rather than aggressive. As you read on, you will see how this latest move fits into the evolving Biocon narrative and what to watch next as new...

Moby summary of Bio-Rad Laboratories, Inc.'s Q2 2026 earnings call

Bio-Rad Laboratories Inc (BIO) navigates mixed Q2 with strong Digital PCR growth and Clinical Diagnostics recovery, offset by Life Science softness and China headwinds.

Bio-Rad Laboratories (NYSE:BIO) reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in academic research markets weighed on its Life Science segment. Pre

Bio-Rad (BIO) delivered earnings and revenue surprises of +11.97% and -0.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Organic revenue still fell, yet a segment returning to growth and a raised outlook were enough to reprice the stock in a single session.